【摘要】：目的 探討卵巢癌、良性卵巢腫瘤和正常卵巢組織中Id1(inhibitor of differentiation or DNA bindingl)和HtrA1(high temperature requirement factorl)的表達(dá)及其與臨床病理參數(shù)的關(guān)系。 方法 (1)收集青島大學(xué)醫(yī)學(xué)院附屬醫(yī)院婦科40例卵巢上皮癌組織(化療敏感組：20例、耐藥組：20例)、10例良性卵巢腫瘤組織及10例正常卵巢組織。 (2)應(yīng)用免疫組化SP的方法檢測(cè)Id1和HtrA1在上皮性卵巢癌、良性卵巢腫瘤及正常的卵巢組織中表達(dá)。 (3)統(tǒng)計(jì)病人的年齡、腫瘤大小、術(shù)前CA125值、術(shù)前腹水量、腫瘤的組織學(xué)類型、病理分級(jí)程度、臨床分期及其淋巴結(jié)的轉(zhuǎn)移情況,并觀察上述臨床病理參數(shù)與Idl和HtrA1的表達(dá)的關(guān)系。 (4)探討卵巢上皮癌組織中Id1和HtrA1的表達(dá)關(guān)系。 結(jié)果 (1)卵巢癌組織中Id1的表達(dá)陽性率為77.5%,明顯高于良性卵巢腫瘤組織(40%,P0.05)和正常卵巢組織(30%,PO.05)。卵巢癌組織中HtrA1表達(dá)陽性率為22.5%,明顯低于良性卵巢腫瘤組織(40%,P0.05)和正常卵巢組織(60%,P0.05)。 (2)卵巢癌耐藥組中Id1陽性表達(dá)率為95%明顯高于敏感組(60%,P0.05)。卵巢癌耐藥組中HtrA1陽性表達(dá)率為5%明顯低于敏感組(40%,P0.05)。 (3)患者術(shù)前CA125水平、病理分級(jí)和淋巴結(jié)轉(zhuǎn)移分別與Idl和HtrA1的表達(dá)密切相關(guān)(P0.05)。 (4)Idl和HtrA1的表達(dá)呈負(fù)相關(guān)(r=-0.186,P=0.045)。 結(jié)論 (1)正常卵巢和良性卵巢腫瘤組織Id1陽性表達(dá)率較低,卵巢癌組織中陽性表達(dá)率較高,隨組織惡變其表達(dá)率明顯升高。而HtrA1則隨組織惡變表達(dá)降低。 (2)隨著卵巢上皮癌組織中Id1表達(dá)升高和HtrA1的表達(dá)降低,耐藥性增加。 (3)Id1高表達(dá)和HtrA1低表達(dá)與卵巢上皮癌的化療耐藥及預(yù)后關(guān)系密切。
[Abstract]:Objective to investigate the expression of Id1 (inhibitor of differentiation or DNA bindingl) and HtrA1 (high temperature requirement factorl) in ovarian carcinoma, benign ovarian tumor and normal ovarian tissue and their relationship with clinicopathological parameters. Methods (1) 40 cases of ovarian epithelial carcinoma (chemosensitive group: 20 cases, drug-resistant group: 20 cases), 10 cases of benign ovarian tumor tissue and 10 cases of normal ovarian tissue were collected. (2) the expression of Id1 and HtrA1 in epithelial ovarian carcinoma, benign ovarian tumor and normal ovarian tissue were detected by immunohistochemical SP method. (3) the patient's age, tumor size, preoperative CA125 value, preoperative ascites volume, histological type of tumor, pathological grade, clinical stage and lymph node metastasis were analyzed. The relationship between the above clinicopathologic parameters and the expression of Idl and HtrA1 was observed. (4) to investigate the expression of Id1 and HtrA1 in epithelial ovarian carcinoma. Results (1) the positive rate of Id1 expression in ovarian cancer tissue was 77.5, which was significantly higher than that in benign ovarian tumor tissue (40 ovarian tumor tissues) and normal ovarian tissue (30jiao. 05). The positive rate of HtrA1 expression in ovarian cancer tissues was 22.5%, which was significantly lower than that in benign ovarian tumor tissues (40% P0.05) and normal ovarian tissues (60% P0.05). (2) the positive expression rate of Id1 in drug-resistant ovarian cancer group was 95% significantly higher than that in sensitive group (P 0.05). The positive expression rate of HtrA1 in drug-resistant ovarian cancer group was significantly lower than that in sensitive group (5% vs 40%, P0.05). (3) preoperative CA125 level, pathological grade and lymph node metastasis were closely related to the expression of Idl and HtrA1 (P0.05). (4) there was a negative correlation between the expression of Idl and HtrA1 (r = -0.186, P = 0.045). Conclusion (1) the positive expression rate of Id1 in normal and benign ovarian tumor tissues is lower than that in ovarian cancer tissue. However, the expression of HtrA1 decreased with the malignant change of tissue. (2) Drug resistance increased with the increase of Id1 expression and the decrease of HtrA1 expression in epithelial ovarian carcinoma. (3) the high expression of Id1 and the low expression of HtrA1 were closely related to the chemotherapeutic resistance and prognosis of ovarian epithelial carcinoma.
【學(xué)位授予單位】：青島大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2014
【分類號(hào)】：R737.31

【參考文獻(xiàn)】

相關(guān)期刊論文 前1條

1 張濤;江普查;;分化抑制因子Id1與惡性腫瘤血管生成的研究進(jìn)展[J];鄖陽醫(yī)學(xué)院學(xué)報(bào);2009年01期

，

本文編號(hào)：2379087